COPD Raises Risk of Mortality in Finland, Population Study Finds

Chronic obstructive pulmonary disease (COPD) was associated with an increased risk of overall mortality, as well as higher chances of cardiovascular, respiratory, and cancer-associated deaths, in a group of people living in Finland, a recent study has found. While asthma was also linked to a higher mortality risk over…

Tudorza Reduces COPD Flare-ups Without Increasing Risk of Cardiovascular Complications or Death, Phase 4 Trial Shows

Tudorza (aclidinium bromide) reduces flare-ups in patients with moderate to severe chronic obstructive pulmonary disease (COPD) without increasing the risk of cardiovascular complications such as heart attack and stroke, or death, data from a Phase 4 trial show. The findings were discussed by Robert Wise, MD,…

Circassia Adding Cardiovascular Safety Data on Tudorza Label for COPD Patients

The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application for the addition of new clinical data on on the label of Tudorza (aclidinium bromide), a bronchodilator for the long-term treatment of chronic obstructive pulmonary disease (COPD) marketed by Circassia Pharmaceuticals…